- Home
- LGO vs AGEN Comparison
LGO vs AGEN Comparison
Compare LGO & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LGO
- AGEN
- Stock Information
- Founded
- LGO 1988
- AGEN 1994
- Country
- LGO Canada
- AGEN United States
- Employees
- LGO N/A
- AGEN N/A
- Industry
- LGO
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LGO
- AGEN Health Care
- Exchange
- LGO Nasdaq
- AGEN Nasdaq
- Market Cap
- LGO 100.0M
- AGEN 87.7M
- IPO Year
- LGO 2007
- AGEN 2000
- Fundamental
- Price
- LGO $1.50
- AGEN $5.07
- Analyst Decision
- LGO Strong Buy
- AGEN Buy
- Analyst Count
- LGO 1
- AGEN 2
- Target Price
- LGO $3.70
- AGEN $14.50
- AVG Volume (30 Days)
- LGO 132.7K
- AGEN 438.9K
- Earning Date
- LGO 08-12-2025
- AGEN 08-11-2025
- Dividend Yield
- LGO N/A
- AGEN N/A
- EPS Growth
- LGO N/A
- AGEN N/A
- EPS
- LGO N/A
- AGEN N/A
- Revenue
- LGO $108,526,000.00
- AGEN $101,706,000.00
- Revenue This Year
- LGO N/A
- AGEN $26.25
- Revenue Next Year
- LGO $54.96
- AGEN N/A
- P/E Ratio
- LGO N/A
- AGEN N/A
- Revenue Growth
- LGO N/A
- AGEN N/A
- 52 Week Low
- LGO $1.12
- AGEN $1.38
- 52 Week High
- LGO $2.84
- AGEN $7.34
- Technical
- Relative Strength Index (RSI)
- LGO 55.80
- AGEN 58.28
- Support Level
- LGO $1.32
- AGEN $4.12
- Resistance Level
- LGO $1.56
- AGEN $4.37
- Average True Range (ATR)
- LGO 0.08
- AGEN 0.26
- MACD
- LGO 0.00
- AGEN 0.07
- Stochastic Oscillator
- LGO 75.00
- AGEN 98.98
About LGO Largo Inc.
Largo Inc is committed to the production and supply of high-quality vanadium products. The company is also focused on the advancement of renewable energy storage solutions through Largo Clean Energy and its vanadium redox flow battery technology. The Company is engaged in the mining, exploration, and development of mineral properties, predominantly in Brazil, through which it produces and supplies vanadium products VPURE Flake, VPURE+ Flake, and VPURE+ Powder. The company has operating segments: sales & trading, mine properties, which generates key revenue, corporate, exploration and evaluation properties, Clean Energy, and Largo Physical Vanadium.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).